Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Phase III trial shows vosaroxin improves overall survival in acute myeloid leukaemia

Farhad Ravandi • 6 Dec 2014
ASH 2014
Acute Myeloid Leukemia Cytarabine Vosaroxin

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Farhad Ravandi (The University of Texas MD Anderson Cancer Center, Houston, TX) discusses the phase III double-blind randomized controlled multinational VALOR study, which evaluated vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first-relapsed or refractory acute myeloid leukaemia.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Farhad Ravandi

Can persistent MRD negativity be considered therapy failure in AML? ELN definitions and relapse risk
2:04
Can persistent MRD negativity be considered therapy failure in AML? ELN definitions and relapse risk
Farhad Ravandi • 21 Sep 2026
Refining the role of MRD in AML: predicting relapse and the goal of MRD negativity
1:40
Refining the role of MRD in AML: predicting relapse and the goal of MRD negativity
Farhad Ravandi • 21 Sep 2026
Will MRD eradication become a routine treatment goal in AML?
1:09
Will MRD eradication become a routine treatment goal in AML?
Farhad Ravandi • 21 Sep 2026
Can current MRD assays accurately predict relapse in AML? Limitations and future directions
2:18
Can current MRD assays accurately predict relapse in AML? Limitations and future directions
Farhad Ravandi • 21 Sep 2026

Related Videos

Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
8:41
Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
Roland Walter • 20 Sep 2026
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
8:33
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
Hima Atluri • 20 Sep 2026
How and when to use oral decitabine in AML
12:38
How and when to use oral decitabine in AML
Gail Roboz • 20 Sep 2026
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
22:07
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
Amir Fathi • 20 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals